Trinity Biotech (TRIB) Cash & Current Investments (2016 - 2025)
Trinity Biotech's Cash & Current Investments history spans 17 years, with the latest figure at $5.1 million for Q4 2025.
- On a quarterly basis, Cash & Current Investments fell 3.66% to $5.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.1 million, a 3.66% decrease, with the full-year FY2025 number at $5.1 million, down 3.66% from a year prior.
- Cash & Current Investments hit $5.1 million in Q4 2025 for Trinity Biotech, up from $1.6 million in the prior quarter.
- Over the last five years, Cash & Current Investments for TRIB hit a ceiling of $28.6 million in Q2 2021 and a floor of $152000.0 in Q1 2023.
- Historically, Cash & Current Investments has averaged $12.2 million across 5 years, with a median of $6.6 million in 2022.
- Biggest five-year swings in Cash & Current Investments: surged 106.33% in 2021 and later plummeted 99.42% in 2023.
- Tracing TRIB's Cash & Current Investments over 5 years: stood at $25.9 million in 2021, then plummeted by 74.12% to $6.7 million in 2022, then crashed by 42.31% to $3.9 million in 2023, then soared by 37.84% to $5.3 million in 2024, then decreased by 3.66% to $5.1 million in 2025.
- Business Quant data shows Cash & Current Investments for TRIB at $5.1 million in Q4 2025, $1.6 million in Q2 2025, and $5.3 million in Q4 2024.